Online inquiry

IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11354MR)

This product GTTS-WQ11354MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Neuromyelitis optica (NMO) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11354MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8651MR IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HuMax-CD38
GTTS-WQ9793MR IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA JS002
GTTS-WQ10386MR IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA LY2127399
GTTS-WQ11457MR IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MEDI-9447
GTTS-WQ13799MR IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN-10933
GTTS-WQ6681MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA DMUC5754A
GTTS-WQ4413MR IVTScrip™ mRNA-Anti-TNFRSF9, BMS-663513(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-663513
GTTS-WQ2166MR IVTScrip™ mRNA-Anti-IL6, ALD-518(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ALD-518
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW